ALK

Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD
GPCR & G Protein

5-HT Receptor Adenosine Receptor Adenylate Cyclase Adrenergic Receptor Angiotensin Receptor APJ Bombesin Receptor Bradykinin Receptor cAMP Cannabinoid Receptor CaSR CCK receptor CCR CGRP Receptor CRFR CXCR Dopamine Receptor EBI2 Endothelin Receptor Formyl Peptide Receptor Free Fatty Acid Receptor G protein-coupled Bile Acid Receptor GCGR GHSR GLP Receptor Glucagon Receptor GnRH Receptor GPCR19 GPR GPR109A Guanylate Cyclase Hedgehog(Smoothened) ROCK Histamine Receptor ICMT Leukotriene Receptor LPA Receptor LPL Receptor LTR mAChR Melanocortin Receptor Melatonin Receptor mGluR Motilin Receptor MRGPR MT Receptor Neurokinin Receptor Neuropeptide Y Receptor Neurotensin Receptor NPY receptor Opioid Receptor OX Receptor Oxytocin Receptor P2Y Receptor PAFR PAR PKD PKG Prostaglandin Receptor Ras RGS Protein S1P Receptor SGLT Sigma Receptor Somatostatin Receptor TAAR TSH Receptor Urotensin Receptor Vasopressin Receptor

+MORE

ALK

Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, is predominantly expressed in the brain and implicated in neuronal development and cognition. Adenosine triphosphate (ATP) and a gamma-phosphate group are transferred via ALK to a tyrosine residue on a substrate protein. As a result, it causes the tyrosine residues in its substrate proteins to phosphorylate. Different enzymes (kinases and phosphatases) catalyze the important protein reactions of phosphorylation and dephosphorylation, which are essential to many cellular processes.

ALK gene activation results from fusion with other oncogenes (NPM, EML4, TIM, etc.) or gene amplification, mutation, or protein overexpression and contributes to the development of several human cancers, including anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors, and neuroblastoma. ALK is a transmembrane tyrosine kinase receptor that dimerizes and then autophosphorylates the intracellular kinase domain in response to ligand binding to its extracellular domain. Specific inhibitors, like Crizotinib, Ceritinib, Alectinib, etc., have shown to be highly effective in treating ALK-positive non-small cell lung cancer in particular when it becomes activated in cancer.

ALK related products

Cat No.	Product Name	CAS No.	Product Description
V0606	Alectinib (AF-802, CH-5424802, RO-5424802, Alecensa)	1256580-46-7	Alectinib (formerly AF802, CH5424802, RO5424802; trade name Alecensa) is a potent, selective, and orally bioavailable ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor with potential antitumor activity.
V0070	Alectinib HCl (ALECENSA, AF-802, CH-5424802, RO-5424802)	1256589-74-8	Alectinib HCl (formerly AF802, CH5424802 or RO5424802; trade name ALECENSA) is a potent, selective, and orally bioavailable inhibitor of ALK (anaplastic lymphoma kinase) tyrosine kinase with IC50 value of 1.9 nM in cell-free assays.
V3324	ALK inhibitor 2	761438-38-4	ALK inhibitor 2 is a novel, potent and selective inhibitor for the ALK kinase (anaplastic lymphoma kinase).
V0612	ASP3026	1097917-15-1	ASP3026 (ASP-3026; ASP 3026) is an orally bioavailable inhibitor of ALK (anaplastic lymphoma kinase) with potential antineoplastic activity.
V0611	AZD3463	1356962-20-3	AZD-3463 (AZD3463) is a novel, potent and selective ALK/IGF1R inhibitor with potential anticancer activity.
V2755	Belizatinib	1357920-84-3	Belizatinib, formerly known as TSR-011, isa potent,orally bioavailable dual inhibitor ofALK (anaplastic lymphoma kinase) with IC50 of 0.7 nM and an inhibitor oftropomyosin receptor kinase (TRK)with IC50 values less than 3 nM for TRK A, B, and C.
V0607	Brigatinib (AP26113)	1197953-54-0	Brigatinib (formerly AP26113;AP-26113; ALK-IN-1; trade name:Alunbrig) is an orally bioavailable, FDA-approved and selective ALK (anaplastic lymphoma kinase) inhibitor with potential antineoplastic activity.
V3921	BRIGATINIB ANALOG	1197958-12-5	Brigatinib analog is a derivative of Brigatinib (AP-26113; Alunbrig), which is an orally bioavailable ALK (anaplastic lymphoma kinase) inhibitor approved by FDA in 2017 for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC).
V78550	Brigatinib-13C6 (AP-26113-13C6)		Brigatinib-13C6 is a 13C (carbon 13)-labeled Brigatinib.
V17903	CEP-28122	1022958-60-6	CEP-28122 is a novel, potent, selective and orally bioavailable ALK inhibitor with a favorable pharmacodynamic and pharmacokinetic profile and robust and selective pharmacologic efficacy against ALK-positive human cancer cells and tumor xenograft models in mice.
V77157	CEP-28122 mesylate salt		CEP-28122 mesylate salt is a diaminopyrimidine analogue that is a specific and orally bioactive ALK inhibitor (antagonist) with IC50 of 1.9 nM for recombinant ALK kinase activity.
V0154	Ceritinib (LDK-378; Zykadia)	1032900-25-6	Ceritinib (formerly known as LDK378; tradename: Zykadia) is novel, potent and selectiveinhibitor against ALK (anaplastic lymphoma kinase positive) with potential anticancer activity.
V17933	Ceritinib diHCl	1380575-43-8	Ceritinib diHCl (LDK-378; LDK378; Zykadia; Spexib), the dihydrochloride salt of ceritinib, is an ALK (anaplastic lymphoma kinase positive) inhibitor approved in 2014 for the treatment of non-small cell lung cancer (NSCLC).
V32937	Crizotinib HCl	1415560-69-8	Crizotinib HCl (formerly known as PF-02341066 hydrochloride; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
V2779	Ensartinib	1370651-20-9	Ensartinib (formerly known as X-396) is a novel, highlypotent andselective,orally available small molecule inhibitor of ALK (anaplastic lymphoma kinase) with an IC50 less than 4 nM in Ambit assays.
V31650	Ensartinib hydrochloride ( X396)	2137030-98-7	Ensartinib (formerly known as X-396) is a novel, highlypotent, selective,andorally available small molecule inhibitor of ALK (anaplastic lymphoma kinase) with an IC50 less than 4 nM in Ambit assays.
V0609	Entrectinib (NMS-E 628; RXDX101; ROZLYTREK)	1108743-60-7	Entrectinib (formerly also known as NMS-E628; RXDX-101; trade nameROZLYTREK) is a potent and orally bioavailable small molecule inhibitor of TrkA, TrkB, TrkC, ROS1 and ALK with potential antitumor activity.
V0608	GSK1838705A	1116235-97-2	GSK1838705A (GSK-1838705A) is a novel, potent and reversible small-molecule IGF-1R inhibitor with potential anticancer activity.
V3374	HG-14-10-04	1356962-34-9	HG-14-10-04 is a novel, potent and specific ALK (Anaplastic lymphoma kinase) inhibitor with IC50 of 20The anaplastic lymphoma kinase (ALK) gene plays an important physiologic role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL).
V23301	KRCA-0008	1472795-20-2	KRCA-0008 is a novel, potent dual inhibitor of Ack1 and anaplastic lymphoma kinase (ALK)with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.